Latest FDA-approved drug nirsevimab-alip (Beyfortus): A gamechanger for treatment of respiratory syncytial virus
J Med Virol
.
2023 Oct;95(10):e29169.
doi: 10.1002/jmv.29169.
Authors
Muhammad Talha
1
,
Mohammad Haris Ali
1
Affiliation
1
Department of Pediatrics, Shaikh Khalifa Bin Zayed Al-Nahyan Medical and Dental College, Lahore, Pakistan.
PMID:
37815045
DOI:
10.1002/jmv.29169
No abstract available
Publication types
Letter
MeSH terms
Antibodies, Monoclonal, Humanized / therapeutic use
Humans
Respiratory Syncytial Virus Infections* / drug therapy
Respiratory Syncytial Virus, Human*
Substances
nirsevimab
Antibodies, Monoclonal, Humanized